Thrombin inhibitor

Thrombin inhibitor

Thrombin inhibitors are one type of anticoagulant medication, used to help prevent formation of harmful blood clots in the body by blocking the activity of thrombin.
Gale Encyclopedia of Medicine. Copyright 2008 The Gale Group, Inc. All rights reserved.
References in periodicals archive ?
Veltkamp, Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran.
Dabigatran is a new oral anticoagulant that works as a direct thrombin inhibitor. (1) Approved by the Food and Drug Administration in October 2010 as the first available oral anticoagulant alternative to warfarin in the United States for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, (1,2) it has a rapid onset of action with predictable pharmacokinetics that does not require routine blood monitoring.
The product is a direct thrombin inhibitor indicated for use as an anticoagulant in patients.
One of them is dabigatran etexilate, a thrombin inhibitor and ravaroxiban (Xeralto), a factor Xa inhibitor.
[2] Nonstandard abbreviations: SCD, sickle cell disease; RBC, red blood cell; DTI, direct thrombin inhibitor; HIT, heparin-induced thrombocytopenia; PTT, partial thromboplastin time; MSG, monosodium glutamate; AST, aspartate transaminase; SAM, 5-adenosyl methionine; t-PA, tissue plasminogen activator; NAC, N-acetyl-L-cysteine; ALT, alanine transaminase.
These agents, which include the factor Xa inhibitors rivaroxaban (Xarelto), apixaban (Eliquis), and edoxaban (Savaysa), and the competitive thrombin inhibitor dabigatran (Pradaxa), often are preferred over warfarin because of their more predictable pharmacokinetics, comparable efficacy, comparable or lower risk of major bleeding complications, fewer drug interactions, and lack of need for frequent monitoring.
Bivalirudin is a specific and direct thrombin inhibitor indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention.
Bivalirudin is a specific and direct thrombin inhibitor indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention, a common non-surgical procedure to treat blocked or narrowed blood vessels in the heart.
In a similar study previously conducted by our group, argatroban (a direct thrombin inhibitor) was able to mask the diagnosis of FVL by raising the APCR ratio into the normal range, (17) and dabigatran (direct thrombin inhibitor) substantially raised the APCR ratio.
Additionally, dabigatran has a different mechanism of action; it is a direct thrombin inhibitor [39, 40].
The AHA/ASA guidelines do not recommend IVT for patients on warfarin with an INR > 1.7 and/or a PT > 15 seconds, patients who received a therapeutic dose of LMWH in the last 24 hours, or patients taking a direct thrombin inhibitor or a factor Xa inhibitor, unless coagulation tests (e.g., aPTT, INR, platelet count, ecarin clotting time, thrombin time, or appropriate direct factor Xa activity assays) are normal, or more than 48 hours have passed since the last dose (assuming normal renal function) [9].